Research & Development: Page 3
-
Permission granted by Memorial Sloan Kettering Cancer Center
To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’
A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.
By Michael Gibney • Nov. 16, 2022 -
Permission granted by Sana Alajmovic
ProfileA ‘bold vision’ to prevent diabetes
Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts.
By Alexandra Pecci • Nov. 15, 2022 -
iStock via Getty Images
4 ways to bring COVID’s ‘warp speed’ to the next era of drug development
An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.
By Kelly Bilodeau • Nov. 14, 2022 -
Permission granted by Medidata
Q&AThe legacy of Glen de Vries: Our last interview with the pioneering entrepreneur
Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.
By Taren Grom • Nov. 11, 2022 -
Permission granted by Lene Oddershede
Q&ANovo Nordisk’s quantum bet on ‘world changing’ computing
Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.
By Taren Grom • Nov. 10, 2022 -
Permission granted by Cresilon
ProfileThis plant-based gel stops bleeding in seconds — and might have potential in drug delivery
29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.
By Karissa Waddick • Nov. 9, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: 82VS’s Trier Bryant
Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...
By Taren Grom • Nov. 9, 2022 -
Permission granted by Rami Elghandour
ProfileChasing that ‘Time magazine cover potential’
Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.
By Alexandra Pecci • Nov. 8, 2022 -
Amornrat Phuchom via Getty Images
While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help
Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.
By Michael Gibney • Nov. 8, 2022 -
Stock via Getty Images
After numerous setbacks, here’s where the Huntington’s pipeline stands
A look at emerging treatments and where there’s hope for patients.
By Kelly Bilodeau • Nov. 7, 2022 -
Christopher Furlong / Staff via Getty Images
‘Zombie’ cells, Shkreli and cats — new research in toxoplasmosis and how the three are connected
Toxoplasmosis is carried by about a third of the world’s population, but effective drugs are lacking — now researchers have discovered a key infection element that could lead to better treatment.
By Michael Gibney • Nov. 3, 2022 -
Stock via Getty Images
Acumen cruises into the fast lane with novel Alzheimer’s treatment
The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.
By Meagan Parrish • Nov. 3, 2022 -
Spencer Platt via Getty Images
Q&ATuberculosis patients haven’t seen new treatments in 40 years – now Merck and Gates MRI have teamed up to change that
The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.
By Alexandra Pecci • Nov. 1, 2022 -
Retrieved from Google image.
While DCTs get all the hype, some industry insiders say the future is a digital hybrid
Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.
By Michael Gibney • Nov. 1, 2022 -
iStock via Getty Images
Tips for tackling trial recruitment and retention woes in oncology
How new tools are helping companies find and keep cancer patients in clinical studies.
By Kelly Bilodeau • Oct. 31, 2022 -
Permission granted by Biogen
Riches, rags, riches: Is Biogen the Cinderella of biotechs?
Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.
By Michael Gibney • Oct. 27, 2022 -
iStock via Getty Images
Q&A // Biotech SpotlightThe first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology
Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.
By Karissa Waddick • Oct. 27, 2022 -
Justin Sullivan/Staff via Getty Images
Q&ANobel Prize winner Carolyn Bertozzi on revealing the power of chemistry in drug development
The Stanford researcher and biotech entrepreneur discusses how click and bioorthogonal chemistry could revolutionize drug development.
By Karissa Waddick • Oct. 26, 2022 -
Permission granted by Tasuku Kitada
ProfileA longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level
The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.
By Alexandra Pecci • Oct. 25, 2022 -
Stock via Getty Images
Beyond cancer: Scientists push CAR-T cell therapies into new frontiers
Why a ‘very exciting’ trial of the therapy in lupus patients could swing the door open to new studies in autoimmune diseases.
By Kelly Bilodeau • Oct. 24, 2022 -
Stock via Getty Images
OpinionWhat’s keeping pharma leaders up at night
C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.
By Taren Grom • Oct. 21, 2022 -
Stock illustration via Getty Images
ProfileHow a company aimed at bringing the woolly mammoth back to life spun off a startup that could speed drug development
Colossal Biosciences announced the creation of Form Bio — and its “operating system for science” — in September.
By Alexandra Pecci • Oct. 20, 2022 -
Stock via Getty Images
5 impactful drug trial failures from the last year
Major recent trial flops and what they mean for companies, patients and the industry.
By Meagan Parrish • Oct. 19, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Exscientia’s Charlotte Deane
Is the industry ready for a biologic discovery revolution? Charlotte Deane, chief scientist of biologics AI at Exscientia, thinks so.
By Taren Grom • Oct. 19, 2022 -
Stock via Getty Images
A new class of drugs with ‘huge’ potential in the fight against challenging breast cancers
Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.
By Kelly Bilodeau • Oct. 18, 2022
Previous
